Humedix Co., Ltd. (200670.KQ) Stock

200670.KQ logo

Humedix Co., Ltd.

200670.KQSouth Korea
Healthcare

Company profile

Humedix reported revenue of 170.05 billion KRW for fiscal year 2025, up 5.1% from fiscal year 2024, and net income of 51.79 billion KRW. That is a net profit margin of 30.5% for fiscal year 2025. In Q1 2026 (the quarter ended March 31, 2026) revenue was 40.52 billion KRW, up 1.0% from a year before. In Q1 2026 it reported net income of 13.00 billion KRW, against net income of 13.44 billion KRW a year earlier. Our analysis of its filings shows revenue growing from 152.27 billion KRW in fiscal year 2023 to 170.05 billion KRW in fiscal year 2025, 5.7% a year on average.

What stands out

  • Revenue and net income in fiscal year 2025 were the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Humedix Co., Ltd.

Humedix Co., Ltd. engages in the manufacture and sale of various pharmaceutical products in South Korea. The company offers prescription medicines, active pharmaceutical ingredients, medical devices, cosmetics, and health functional food products. It is also involved in the manufacture and distribution of anticancer drugs. The company was formerly known as HVLS Co., Ltd. and changed its name to Humedix Co., Ltd. in 2010. Humedix Co., Ltd. was founded in 2002 and is headquartered in Seongnam-si, South Korea.

Largest shareholders

  • Huons Global Co., Ltd.36.08%
  • VIP Research & Management Inc.4.51%
  • Humedix Co., Ltd.2.77%
  • Yeon-sang Yoon1.195 %1.20%
  • Dong-Cheol Son0.061 %0.06%

Share of the company, as of September 25, 2026

Leadership

  • Min-jong Kang — Chief Executive Officer

How much revenue does Humedix make?

Humedix reported 170.05 billion KRW in revenue for fiscal year 2025, up 5.1% from 161.87 billion KRW in fiscal year 2024. In Q1 2026 revenue was 40.52 billion KRW.

What companies are similar to Humedix?

Listed companies of a similar size in the same industry (various healthcare equipment manufacturing) include PharmaResearch Co., Ltd. (214450.KQ), Rokit Healthcare Inc. (376900.KQ), Synergy Innovation Co., Ltd. (048870.KQ), Selvas Healthcare, Inc. (208370.KQ).

How has Humedix's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 110.99 billion KRW; FY2022, 123.17 billion KRW; FY2023, 152.27 billion KRW; FY2024, 161.87 billion KRW; FY2025, 170.05 billion KRW.

Company Information

SectorHealthcare
IndustryVarious Healthcare Equipment Manufacturing
HeadquartersSeongnam-si, South Korea
ExchangeKOSDAQ
TimezoneAsia/Seoul (KST)

Contact & Links

Address
HuonsGlobal Building, Seongnam-si, 13449
Phone
82 70 7492 5600
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Humedix Co., Ltd. (200670.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/200670.KQ

LinkedInLinkedInXXYouTubeYouTube